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Carsten Denkert5, Imre Pete6 and Balázs Győrffy1,7,8*Abstract
Background: Primary systemic treatment for ovarian cancer is surgery, followed by platinum based chemotherapy.
Platinum resistant cancers progress/recur in approximately 25% of cases within six months. We aimed to identify
clinically useful biomarkers of platinum resistance.
Methods: A database of ovarian cancer transcriptomic datasets including treatment and response information was
set up by mining the GEO and TCGA repositories. Receiver operator characteristics (ROC) analysis was performed
in R for each gene and these were then ranked using their achieved area under the curve (AUC) values. The most
significant candidates were selected and in vitro functionally evaluated in four epithelial ovarian cancer cell lines
(SKOV-3-, CAOV-3, ES-2 and OVCAR-3), using gene silencing combined with drug treatment in viability and apoptosis
assays. We collected 94 tumor samples and the strongest candidate was validated by IHC and qRT-PCR in these.
Results: All together 1,452 eligible patients were identified. Based on the ROC analysis the eight most significant
genes were JRK, CNOT8, RTF1, CCT3, NFAT2CIP, MEK1, FUBP1 and CSDE1. Silencing of MEK1, CSDE1, CNOT8 and RTF1,
and pharmacological inhibition of MEK1 caused significant sensitization in the cell lines. Of the eight genes, JRK
(p = 3.2E-05), MEK1 (p = 0.0078), FUBP1 (p = 0.014) and CNOT8 (p = 0.00022) also correlated to progression free
survival. The correlation between the best biomarker candidate MEK1 and survival was validated in two
independent cohorts by qRT-PCR (n = 34, HR = 5.8, p = 0.003) and IHC (n = 59, HR = 4.3, p = 0.033).
Conclusion: We identified MEK1 as a promising prognostic biomarker candidate correlated to response to
platinum based chemotherapy in ovarian cancer.
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Ovarian cancer is the fifth leading cause of cancer death
among women in the USA, with approximately 22,000 new
cases and 14,000 deaths per year [1]. Primary treatment in-
cludes surgery and platinum-based chemotherapy. To date,
with the exception of bevacizumab, no successful trial has
been conducted identifying any efficient targeted therapy
for ovarian cancer patients [2,3]. Thus, the platinum-taxane
chemotherapy still represents the gold standard of treat-
ment. Following chemotherapy, platinum-resistant cancer* Correspondence: gyorffy.balazs@ttk.mta.hu
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25% of patients within six months [4] and the overall 5-year
survival is only 30% [5].
Platinum agents bind DNA forming inter- and intra-
strand DNA adducts [6]. Cellular perception of these
DNA adducts leads to the activation of DNA-damage
mediated apoptotic pathways. Resistance against carbopla-
tin can evolve by three principal mechanisms: reduction
of intracellular drug concentration (involving alterations
in CTR1, CTR2, ATP7B, GST), changes in DNA repair
(ERCC1, MLH1, MSH2, BRCA1/2) or modification of cel-
lular response (TP53, ERBB2, CCNE) which mechanisms
have been discussed previously [7,8].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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volved in the biological machinery of resistance against
platinum agents, no approved predictive biomarker is yet
available. In addition, some array based studies promised
higher prognostic and predictive efficiency [9]. A 14-gene
predictive model (based on specimens from 79 patients)
was capable to discriminate women at risk for early versus
late relapse after initial chemotherapy [10]. Spentzos and
colleagues identified a 115-gene expression set as a prog-
nostic marker (Ovarian Cancer Prognostic Profile) in 68
patients [11]. A 300-gene ovarian prognostic index was
identified in 80 patients and validated in an independent
set of 118 patients [12]. However, these gene sets share
only a minimal number of genes, which draws attention
to the following important points: high sample numbers
are necessary to have a representative picture of the
patient population, identical platforms must be used, and
unbiased pre-processing methods have to be applied [13].
In present study, our aim was to identify predictive
gene expression markers based on a large patient cohort
established using reproducible analysis steps. The in silico
identified strongest gene candidates were then further
assessed in vitro. Finally, clinical applicability of the
most promising candidate was tested in two independent
patient cohorts.
Methods
Set-up of microarray databank
We searched GEO (http://www.pubmed.com/geo) and
TCGA (http://cancergenome.nih.gov) to identify datasets
suitable for the analysis. In this, the keywords “ovarian”,
“cancer”, “survival”, “GPL96”, “GPL570” and “GPL571”
were used. Only publications with available raw microarray
gene expression data, clinical treatment and response infor-
mation, and at least 20 patients were included. Only three
microarray platforms, GPL96 (Affymetrix HG-U133A),
GPL570 (Affymetrix HG-U133 Plus 2.0), and GPL571/
GPL3921 (Affymetrix HG-U133A 2.0) were considered.
Bioinformatic processing
Raw .CEL files were MAS5 normalized in the R statistical
environment (www.r-project.org) using the affy Biocon-
ductor library [14]. For the analysis, only probes measured
on GPL96, GPL570 and GPL571/GPL3921 were retained
(n = 22,277). Then, a second scaling normalization was
performed to set the average expression on each chip to
1000 to reduce batch effects [15]. The package “roc” was
used to calculate AUC and significance, and to plot ROC
curves to compare responders and non-responders.
Kaplan-Meier survival plots were calculated and plotted
in R using the “survplot” function of the “survival” Biocon-
ductor package to assess the correlation between survival
and gene expression [16]. To elaborate the three previ-
ously reported potential mediator mechanism of MEK1 incarboplatin resistance (see Discussion), we have set up
metagenes using the mean expression of genes involved in
the AKT pathway (AKT1, PI3KCA, MDM2, MTOR)
and epithelial–mesenchymal transition inducers (EMT;
including CDH1, SNAI1, SNAI2, ZEB1, ZEB2, E47,
KLF8, TWIST, TCF4, SIX1, FOXC2). Finally, Spearman
rank correlation was computed between expression of
MEK1 and ERCC1, and the AKT and EMT metagenes. An
overview of the study and the bioinformatical processing
is exhibited in Figure 1.
Cell culture
The epithelial ovarian cancer cell lines (obtained from
ATCC) SKOV-3, CAOV-3, ES-2 and OVCAR-3 were cul-
tured in RPMI 1640 media with 10% FBS and antibiotics
(penicillin-streptomycin, amphotericin B and tetracycline).
Mycoplasma tests using Mycosensor PCR Assay Kit
(Agilent) were performed before starting the experi-
ments and BM-Cyclin (Agilent) or ciprofloxacin was
used to eliminate contamination.
Authentication of the cell lines
Authentication was performed for the investigated cell lines
using short tandem repeat (STR) analysis of 10 specific loci
in the human genome and a mouse specific marker. DNA
was isolated from the cell lines with DNeasy Blood and
Tissue Kit (Quiagen), quantity and quality of isolated DNA
were measured by Nanodrop ND-1000 system. DNA
(A260) and protein (A280) concentrations and sample pur-
ity (260/280 ratio) were measured, and only high quality
DNA was used for SRTanalysis. Authentication was carried
out by StemElite ID System at the Fragment Analysis Facil-
ity, Johns Hopkins University. STR profiles of the cell lines
were compared to the STR profile database of the Leibniz
Institute DSMZ - German Collection of Microorganisms
and Cell Cultures (http://www.dsmz.de). All four cell lines
included in this study were contamination-free.
Chemosensitivity testing
MTT Cell Proliferation Kit I (Roche) was used to test
drug sensitivity of the cell lines. In this, 10,000 cells/well
were seeded in 90 μl medium onto 96-well plates in six
repeats. After overnight incubation, carboplatin was
added in increasing grade of approximately 2 μM to
1 mM (corresponding to 0x-40x of the clinically admin-
istered dose) in 10 μl water solution (the table of used
concentrations is presented in Additional file 1: Table S1.).
Control wells were treated with vehicle. After 48 hours of
drug treatment, the experiment was terminated and cells
were stained. The reaction was quantified by measure-
ment of absorbance at 595 nm. The measured value was
corrected with the reference measured at 690 nm. Graph-
Pad Prism 5 was used to determine IC50 values and to
visualize results.
Figure 1 Overview of the study.
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We optimized transfection by employing GAPDH posi-
tive control siRNA (Silencer Select, Life Technologies).
Efficacy of silencing was measured by qRT-PCR (Roche
LightCycler 480 system). The highest silencing efficacy
was achieved with a siRNA concentration of 30 nM and
Lipofectamine RNAiMax transfection reagent. JRK wasTable 1 Candidate biomarkers
Gene Platinum-tre










The eight strongest genes selected for in vitro validation including the results of the
platinum-treated ovarian cancer patients.not expressed in the selected cell lines and was therefore
excluded from the silencing experiment. Silencing efficacy
of two pre-designed Silencer Select siRNAs per gene were
assessed for each selected gene. The oligo with higher
silencing efficiency was selected for performing the drug
combined silencing experiment. The ID-s of the used
siRNA-s are presented in Table 1.ated patients (n = 1,152) siRNA










bioinformatic processing performed using transcriptomic data of 1,145
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To investigate the role of selected genes in carboplatin
resistance, we combined gene silencing and drug treat-
ment. In this, 10,000 cells/well were transfected and
seeded in 90 μl medium onto 96-well plates in six re-
peats. After overnight incubation, carboplatin was added
to the cells at the IC50 dose for each cell line. After a
48 hour drug treatment, cells were stained by MTT. In
each siRNA transfected group, absorbance values of the
drug treated group were normalized to the untreated
group. T-test was used to analyze the difference between
negative control siRNA transfected (carboplatin treated)
and target gene siRNA transfected (carboplatin treated)
groups. Significance level was set at p < 0.01.
Apoptosis analysis
Change in the apoptotic ratio of carboplatin treated cells
as a result of silencing for each of the five genes was
measured by FACS. Measurements were performed in
triplicate. After overnight incubation, transfected CAOV-3
cells were treated with the IC50 dose of carboplatin for
48 hours. Then, apoptosis rate was detected by FITC
Annexin V Apoptosis Detection Kit I (BD Pharmingen)
according to the user’s manual in BD FACS Aria I. Apop-
totic ratio in the silenced groups was compared to the
negative control siRNA transfected cohort. T-test was
used to analyze the difference between groups. Signifi-
cance level was set at p < 0.05.
Pharmacologic MEK1 inhibition
As a pilot experiment, PD0325901, a selective MEK1
inhibitor was used to investigate the sensitizing effect of
MEK1 inhibition. Two cell lines (SKOV-3, CAOV-3) were
treated with increasing concentrations of PD0325901 for
48 hours and then stained with MTT. After determining
the sensitivity profile for each cell line against PD0325901,
an experiment was set up using the approximate IC50 or
a less effective dose of carboplatin, alone and in combin-
ation with an effective dose of PD0325901. PD0325901
was dissolved in DMSO, carboplatin was dissolved in
water, and DMSO alone was used as a vehicle. Viability
was normalized to the vehicle treated control; t-test was
used to evaluate the results. Significance level was set
at p < 0.05.
Clinical sample collection
Fresh-frozen and paraffin-embedded samples were col-
lected at the National Institute of Cancer (OOI) Budapest,
Hungary as described previously [17] and at the Charité
Universitätsmedizin Berlin, Germany between 2005 and
2010. For the qRT-PCR measurements, samples were
stored at −80 Celsius degrees until RNA isolation. Tissue
microarray samples were constructed at the Pathology
Institute of the Charité Medical University Berlin. Theinstitutional ethic committees (Ethikausschuss 1 am
Campus Charité Mitte and Országos Onkológiai Intézet,
Intézeti Kutatásetikai Bizottság - OOI IKEB), approved
the study with following reference numbers: EA1/139/05
Amend 2013 (Charité) and OOI-Ált-9444-1/2013/59
(OOI).
RNA isolation and quality control
Frozen biopsy samples were lysed and homogenized in
the mixture of 300 μl GITC containing lysis buffer and
3 μl b-mercaptoethanol by Polytron homogenizator for
30–40 sec., then digested in Proteinase K solution at 55
Celsius for 10 min. RNeasy kit (Quiagen) was used for
RNA isolation. After removing genomic DNA by DNase
I treatment, the total RNA was eluted in 50 μl RNase
free water. Quantity and quality of the isolated RNA
were tested by Nanodrop1000 system and by gel electro-
phoresis using Agilent Bioanalyzer system. Only samples
providing high quality, intact total RNA and showing
regular 18S and 28S ribosomal RNA bend pattern on the
Bioanalyzer analysis were used for PCR.
Immunhistochemistry
TMA blocks were cut 4 μm thick sections for immuno-
histochemistry onto charged SuperFrost Ultra Plus glass
slides (Menzel). Routine dewaxing of the sections in xylene
and descending ethanol series was followed by endogenous
peroxidase blocking using 1% hydrogen peroxide in metha-
nol for 30 min. For antigen retrieval sections were boiled
(~100°C) in 500 ml of 0.01 M sodium citrate-citric acid
(citrate pH 6.0) for 40 min in a microwave oven. After
cooling, sections were treated using a 1% bovine serum
albumin sodium azide solution for 20 min. Sections
were then sequentially incubated using rabbit anti-MEK1
(1:50; HPA026430, Sigma Aldrich) overnight, then with
NovoLink detection kit (Leica-NovoCastra) including the
post-primary reagent, and then 20 min with polymer per-
oxidase detection reagent. Peroxidase activity was revealed
using a DAB (diaminobenzidine) hydrogen peroxide
chromogen-substrate kit for 3–8 min under microscopic
control. Between incubations, the sections were washed
using 0.1 M Tris–HCl (pH 7.4) buffered saline (TBS), and
finally counterstained with hematoxylin. Immunostained
slides were digitalized with a Pannoramic Scan 150
(3DHISTECH) under automated white balance using ×20/
NA0.8 Zeiss Plan Apochromat objective and a Hitachi
HV-F22 3-chip CCD SXGA camera, then analyzed using
the Pannoramic Viewer 1.52.2 software through a 24″
Benq LED monitor. The average intensity from four
samples per patients was taken for statistical analysis.
qRT-PCR measurements
Reverse transcriptions were made with SuperScript II
Reverse Transcriptase according to the user’s manual,
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LightCycler 480 DNA SybrGreen Master I (Roche) and
LightCycler 480 instrument (Roche) were used for qRT-
PCR. Gene specific primers were designed using Primer3
software, GAPDH was used as an internal control. All
measurements were performed in triplicate. For the
immunohistochemistry and qRT-PCR measurements,
Cox survival analysis was done to compare the perform-
ance of the candidate genes. Kaplan-Meier survival plots
were generated using WinSTAT 2013 for Microsoft
Excel (Robert K. Fitch Software). In the survival analysis
quartiles were used as cutoff values and the significance
threshold was set at p < 0.05.
Results
Database construction
We identified 1,452 patients in 8 datasets meeting our
criteria in GEO and TCGA (the seven GEO datasets are:
GSE3149, GSE14764, GSE9891, GSE15622, GSE19829,
GSE26712 and GSE18520). The average follow-up for
relapse-free survival is 24.8 months with 731 progressions.
Of these patients, 1,145 received a platinum-based chemo-
therapy and 630 received taxol (614 patients received both
taxol and platinum).
Bioinformatic processing
Using Jetset [18] we have filtered for probe set quality
and included only reliable and specific probe sets in the
statistical evaluation. ROC analysis was performed for all
genes, and the eight genes showing the highest AUC
value and highest significance were selected for further
experiments. The strongest biomarker candidates are
summarized in Table 1. Beside the high AUC values, high
expressions of JRK (p = 3.2E-05), CNOT8 (p = 2.2E-04),
FUBP1 (p = 0.014) and MEK1 (p = 0.0078) also correlated
with worse relapse-free survival.
Chemosensitivity testing
Sensitivity of the investigated cell lines against carboplatin
varied considerably. OVCAR-3 was the most sensitive cell
line, with an approximate IC50 of 57.3 μM, SKOV-3 was
the most resistant, with an approximate IC50 of 211 μM
and the dose–response curve didn’t reach the baseline,
even at the highest concentration, corresponding approxi-
mately to the 40× of the clinically administered dose. The
dose–response curves of the four cell lines are exhibited
in Figure 2A.
Combination of gene silencing and carboplatin treatment
The silencing efficacy of the used siRNAs compared to a
negative siRNA transfected control (measured by qRT-
PCR in triplicates) were 97.7% (CCT3), 98.6% (RTF1),
65% (NFAT2CIP), 98.01% (MEK1), 93.6% (CSDE1), 46.6%
(FUBP1), and 99.6% (CNOT8). To observe the role of theselected genes in carboplatin resistance, we combined
gene silencing and carboplatin treatment. After 48 hours
of treatment, cells were stained with MTT. In each siRNA
transfected group, absorbance values of the drug treated
group were normalized to the untreated group. As
expected, viability of the carboplatin treated cells was 53.6
percent of the viability of the untreated cells, in the nega-
tive control siRNA transfected group (in average of the
four cell lines). In contrast, in case the target genes were
silenced, viability after carboplatin treatment decreased
with 5.2% to 26% compared to the negative control siRNA
transfected, carboplatin treated group (depending on cell
line and gene). Four of the eight investigated genes had
significant sensitization effect in all four cell lines, namely
RTF1, CSDE1, CNOT8 and MEK1 (p < 0.01). Results of
the silencing experiments are exhibited in Figure 2B (non-
significant results are not shown).
Apoptosis assay
Silencing of MEK1 in 300,000 cells caused significant in-
crease in the number of apoptotic cells and significant
decrease in the number of viable cells after 48 hours of
carboplatin treatment (p = 0.0365, Figure 3A). Silencing
of the other four genes had no significant effect on the
ratio of apoptotic cells (data not shown).
Pharmacologic MEK1 inhibition
The selective MEK1 inhibitor PD0325901 was effective in
both investigated cell lines (SKOV-3 and CAOV-3). SKOV-
3 showed higher resistance than CAOV-3 against single
agent PD0325901. Combination treatment was performed
to detect potential synergistic effect of PD0325901 and
carboplatin. The combination treatments had stronger
cytotoxic effect compared to monotherapy treatments
(p < 0.0001, see Figure 3C). Interestingly, combination of
sub-optimal dose of carboplatin with PD0325901 resulted
in massive viability decrease (p < 0.0001). The dose–re-
sponse curves for PD0325901 are exhibited in Figure 3B.
qRT-PCR measurements
All together 44 patient samples were collected at the
National Institute of Oncology. 10 patients, not receiving
a taxol-carboplatin treatment were excluded. The rela-
tive expression values (compared to GAPDH) and the
clinical data of the 34 included patients are listed in
Additional file 2: Table S2. These patients had a mean
relapse-free survival of 25 months. Lower expression of
MEK1 (upper quartile vs. remaining samples) significantly
correlated with longer relapse-free survival (HR = 5.8,
p = 0.003) (Figure 4A).
Immunohistochemistry
All together samples from 73 independent patients were
evaluated. Only patients receiving a platinum-based
Figure 2 Carboplatin sensitivity and silencing of the candidate genes. Dose–response curves of each cell line against carboplatin, after
48 hours drug administration (A). Relative viability after 48 hours carboplatin administration and silencing of four genes compared to the
negative control siRNA transfected groups in each of the four cell lines (mean with SEM) *p < 0.001, **p < 0.01 (B).
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Figure 3 MEK1 inhibition with carboplatin treatment. Silencing of MEK1 significantly increases the ratio of the apoptotic cells, and decrease
the ratio of the viable cells after 48 hours carboplatin treatment compared to the negative control siRNA transfected cells. *: p < 0.05 (A) Dose–response
curves of SKOV-3 and CAOV-3 cell lines against the MEK1 inhibitor PD0325901 (B). Effects of 48 hour treatment with carboplatin and PD0325901 as single
agents and in combination. SKOV-3: C1: 212 μM carboplatin, C2: 141 μM carboplatin, PD: 554 nM PD0325901 in SKOV3 cell line. CAOV-3: C1: 111 μM
carboplatin, C2: 74 μM carboplatin, PD: 277 nM PD0325901 in CAOV-3 cell line (mean with SEM) *p < 0.0001 C).
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(n = 59). Mean overall survival in these patients was
44.6 months. High staining intensity of MEK1 (upper
quartile vs. remaining samples) significantly correlated
with worse overall survival in platinum treated patients
(HR = 4.2, p = 0.03) (see Figure 4B). The clinical data
and detailed results of IHC are listed in Additional
file 3: Table S3.
Comparison of MEK1 mediator mechanisms
We utilized the available genomic data to identify the
most relevant mechanisms linking carboplatin resistance
to MEK1. In this, we computed correlation between
MEK1 and ERCC1, the AKT and EMT metagenes (selec-
tion was based on literature search, see Discussion). The
only one of these displaying a significant correlation was
the AKT pathway (Spearman correlation coefficient (0.2,
p = 2E-12).Discussion
The goal of present study was to identify a predictive bio-
marker of platinum resistance in ovarian cancer. A bottom
up approach was set up using an extensive bioinformatic
data mining process, in which public transcriptomic and
clinical data of more than 1100 ovarian cancer patients
was utilized. This number is higher than in any previous
study thereby providing a robust foundation for our
investigation. Genes showing the highest correlation
with clinical response and survival were validated in
in vitro setting. Finally, the strongest biomarker candi-
date - MEK1 - was validated in two independent clinical
cohorts using qRT-PCR and immunohistochemistry.
The mitogen-activated protein kinase (MAPK) cascade
is a key signal transducer of growth factor induced signals
and a widely used target of small molecular inhibitors
[19,20]. Within this pathway, MEK1 (MAP2K1) is a MAP
kinase kinase impinging on ERK activation, thereby
Figure 4 Correlation between MEK1 expression and survival after
platinum treatment in EOC patients. Expression measured by
qRT-PCR: relapse-free survival of 34 patients with low and high MEK1
expressing tumors (A). Expression tested with IHC: overall survival
of 59 independent patients with low and high MEK1 expression
(B). Representative images of immunohistochemistry, low and high
expression of MEK1 at low and high magnifications (C).
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the main activator of MAPK cascade is overexpressed in
70% of ovarian cancers and is associated with worseprognosis, and chemoresistance. Targeting EGFR has a
moderate effect in ovarian cancer [21], probably due to
collateral escaping mechanisms [22,23], which could be
avoidable by targeting downstream members of the
oncogenic pathway. Rahman and colleagues showed
that there is correlation between MEK1 amplification (a
downstream member of EGFR pathway) and worse
progression-free survival in ovarian carcinoma patients
[24]. The same association was found in a more recent
paper, based on protein profiling data [25]. These are
supporting our result that MEK1 overexpression is an
independent biomarker of worse survival.
MEK1 inhibitors as targeted therapy agents are already
in clinical trials. PD0325901, a selective MEK1 inhibitor -
also used in our experiments - was proved to be effective
in several preclinical models investigating malignant
melanoma and papillary thyroid carcinoma [26,27] and
was already investigated in three clinical trials. Severe
musculoskeletal, neurological, and ocular toxicities lead to
the termination of a phase I study involving 13 patients
with metastatic melanoma, breast or colon cancers [28]. A
phase II study investigating the efficacy of PD0325901 in
non-small-cell lung cancer was terminated in 2007 due to
lack of objective response (unpublished data, clinicaltrials.
gov identifier: NCT00174369). Currently, a phase I study is
recruiting patients with advanced cancer for a combination
trial with two arms: PD-0325901 plus PF-05212384 (an
intravenous PI3K/mTOR inhibitor) and PF-05212384 plus
irinotecan (clinicaltrials.gov identifier: NCT01347866).
There are several cell-line based studies related to MEK
and platinum resistance, although the results are contro-
versial. Some studies show that the platinum induced
MEK and ERK activation and overexpression leads to
apoptosis [29-32]. Meanwhile others, especially the ones
which use ovarian cancer cell lines show the opposite:
MEK1 activation leads to platinum resistance [33,34].
Although these investigations were made in tissue culture,
and there is no previous study which associate MEK1
expression with clinical resistance. One of the potential
mechanisms linking MAPK pathway to platinum resistance
is via a crosstalk with AKT pathway [35]. Overexpression of
AKT was associated with chemotherapy resistance [36,37].
AKT can be activated not only by extracellular growth fac-
tor signals, but by activation of DNA-PK (DNA dependent
protein kinase) which was described to be overexpressed in
platinum resistant high-grade serous ovarian carcinomas
[38]. MEK1 can activate the transcription factor ERK, a key
activator of proliferation signals [39]. Activation of ERK in
cisplatin resistance was shown previously [40]. MEK1 acti-
vation can cause platinum resistance due to the activation
of ERCC1, a well-known molecule in platinum resistance
[41]. ERCC1 is a member of the nucleotide exchange
repair system, and can induce platinum resistance by
removal of platinum adducts from the DNA. Furthermore,
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duced epithelial-mesenchymal transition (EMT). EMT – a
process of epithelial cells losing their epithelial phenotype
and transforming to a mesenchymal cell – correlates with
higher metastatic activity, more aggressive disease and
drug resistance [22]. We computed correlation between
MEK1 and these three features (ERCC1, AKT and EMT)
in the clinical transcriptomic dataset utilized in our study
to rank these mechanisms. We found that only the AKT
pathway showed significant correlation with the MEK1
expression.
One of the histological and molecular subtypes of
ovarian cancer is low-grade serous (LGS) ovarian carcin-
oma characterized by BRAF, KRAS, NRAS and ERBB2
mutation, amplification or overexpression [42,43]. In
addition, LGS tumors are highly resistant to chemother-
apy [44]. These attributes make LGS tumors a rational
candidate for anti-MEK1/2 therapy. In a recent single
arm phase two clinical trial in patients with recurrent
LGS ovarian cancer, the MEK1/2 inhibitor selumetinib
achieved response only in 15% of patients according to
the RECIST criteria [45]. In our study, massive cell death
was observed after inhibition of MEK1 in combination
with even a very low dose of carboplatin. Instead of inhi-
biting MEK1 using a single agent, our results propose to
use it in combination with carboplatin as a sensitizing
agent in high grade tumors.
Conclusion
Since the 1970’s, significant improvement was achieved in
the treatment of ovarian cancer patients and the five-year
overall survival increased by 25 percent [46]. However,
current platinum-based treatment protocols are still far
from optimum, and we can only improve outcome by iden-
tifying and stimulating more robust targets. In our study, by
employing in silico and in vitro analysis coupled with inde-
pendent validation in clinical cohorts, we identified MEK1
as a promising prognostic biomarker candidate correlated
to response to platinum based chemotherapy in ovarian
cancer. Furthermore, we could also restrain platinum resist-
ance by targeting MEK1. Our results could allow the
utilization of a more targeted therapy and the development
of more efficient anticancer therapies for ovarian cancer.
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